Life Cycle Management for Pharmaceutical Product Launches

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Life cycle management (LCM) ultimately drives the long-term success of any pharmaceutical product. This is especially true today, where generic product introductions and the need for patent extensions highlight the tenuous nature of most products’ lives.

This 31-page document details the way pharmaceutical companies begin crafting their LCM plans to maintain flexibility, maximize revenue and extend product lives as long as possible. Pharmaceutical launch teams can use this information to drive the long-term success of any product.

Key topics covered in this document include:
- Blockbuster Life Cycle Management
- Resource Allocation for Life Cycle Management
- Product Life Extension through Multiple Formulations, Decisions and Key Value Drivers
- Market Focus and Formulation Development

Select best practices include:
1. Form strategic teams to manage each product’s life cycle through the development of distinct therapeutic area strategies.
- At one company, cross-functional international project teams oversee new products and recently identified compounds under the guidance of a dedicated project manager.
2. Review LCM strategy consistently to track progress and address gaps.
- One benchmark company conducts annual reviews of its LCM strategy, while another benchmark company develops plans for further stages of the product’s life on an ongoing basis.
3. Engage thought leaders both early on and after launch to shape the product for market success.
- One benchmark partner found the most effective medium of communication was through email and other less personal contact. For specialty drugs, however, the benchmark partner found that the most effective means of communicating with thought leaders was to provide them with hard data and engage them in face-to-face meetings.

This research originated from a Best Practices, LLC consulting project.

Industries Profiled:
Pharmaceutical; Health Care; Biotech; Medical Device

Companies Profiled:
Merck; Sanofi-aventis; Eli Lilly; GlaxoSmithKline; Novartis; Pfizer; Johnson & Johnson; Bristol-Myers Squibb; AstraZeneca; Roche; Schering-Plough

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Lifecycle Management for Pharmaceutical Launches

ID: 4573

Features:

Pages/Slides: 31

Published: Pre-2019

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B6672DAD430C2D6C85256E4500785241
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/life-cycle-management-for-pharmaceutical-launches?opendocument
18
19opendocument
2044.222.134.250
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB